These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15659281)

  • 1. Validation study to evaluate the reproducibility of a candidate in vitro potency assay of newcastle disease vaccines and to establish the suitability of a candidate biological reference preparation.
    Claassen I; Maas R; Oei H; Daas A; Milne C
    Pharmeuropa Bio; 2004 Dec; 2004(1):1-15. PubMed ID: 15659281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility study to evaluate the correlation between results of a candidate in vitro assay and established in vivo assays for potency determination of Newcastle disease vaccines.
    Claassen I; Maas R; Daas A; Milne C
    Pharmeuropa Bio; 2003 Jul; 2003(1):51-66. PubMed ID: 14563308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen content of inactivated Newcastle disease oil emulsion vaccines as an in vitro indicator of potency.
    Maas R; van Diepen M; Komen M; Oei H; Claassen I
    Dev Biol (Basel); 2002; 111():313-8. PubMed ID: 12678255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The quantitative ELISA for inactivated Newcastle antigen: experience report from an OMCL.
    Motitschke A; Jungbäck C
    Dev Biol (Basel); 2012; 134():55-66. PubMed ID: 22888596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The quantitative ELISA for inactivated Newcastle disease virus antigen: development of the test system and the way to a Ph. Eur in vitro potency test.
    Oei HL
    Dev Biol (Basel); 2012; 134():51-3. PubMed ID: 22888595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of haemagglutinin-neuraminidase and fusion protein content with protective antibody response after immunisation with inactivated Newcastle disease vaccines.
    Maas RA; Komen M; van Diepen M; Oei HL; Claassen IJ
    Vaccine; 2003 Jul; 21(23):3137-42. PubMed ID: 12804840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of the inactivating agent on the antigen content of inactivated Newcastle disease vaccines assessed by the in vitro potency test.
    Jagt HJ; Bekkers ML; van Bommel SA; van der Marel P; Schrier CC
    Biologicals; 2010 Jan; 38(1):128-34. PubMed ID: 19716316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen quantification as in vitro alternative for potency testing of inactivated viral poultry vaccines.
    Maas RA; de Winter MP; Venema S; Oei HL; Claassen IJ
    Vet Q; 2000 Oct; 22(4):223-7. PubMed ID: 11087135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of minimum hemagglutinin units in an inactivated Newcastle disease virus vaccine for clinical protection of chickens from exotic Newcastle disease virus challenge.
    Liljebjelke KA; King DJ; Kapczynski DR
    Avian Dis; 2008 Jun; 52(2):260-8. PubMed ID: 18646455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a candidate in vitro potency assay for inactivated Newcastle disease vaccines.
    Maas R; Komen M; Oei H; Claassen I
    Dev Biol (Basel); 2002; 111():163-9. PubMed ID: 12678237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calibration of the Ph. Eur. Biological Reference Preparation (BRP) for tetanus vaccine (adsorbed) batch 3.
    Tierney R; Hockley J; Rigsby P; Terao E; Daas A; Buchheit KH; Sesardic D
    Pharmeur Bio Sci Notes; 2011 Jun; 2011(1):1-26. PubMed ID: 21619853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic differences among Newcastle disease virus strains of different genotypes used in vaccine formulation affect viral shedding after a virulent challenge.
    Miller PJ; King DJ; Afonso CL; Suarez DL
    Vaccine; 2007 Oct; 25(41):7238-46. PubMed ID: 17719150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of the European Pharmacopoeia Biological Reference Preparation (Ph. Eur. BRP) for hepatitis A vaccine type B (Aventis Pasteur) batch 2.
    Buchheit KH; Daas A
    Pharmeuropa Spec Issue Biol; 2002 Jun; 2002(1):95-108. PubMed ID: 12448033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of chickens against overt clinical disease and determination of viral shedding following vaccination with commercially available Newcastle disease virus vaccines upon challenge with highly virulent virus from the California 2002 exotic Newcastle disease outbreak.
    Kapczynski DR; King DJ
    Vaccine; 2005 May; 23(26):3424-33. PubMed ID: 15837366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical evaluation of numbers of animals to be used in vaccine potency testing: a practical approach.
    Akkermans AM; Hendriksen CF
    Dev Biol Stand; 1999; 101():255-60. PubMed ID: 10566799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection and antibody response caused by turkey herpesvirus vector Newcastle disease vaccine.
    Esaki M; Godoy A; Rosenberger JK; Rosenberger SC; Gardin Y; Yasuda A; Dorsey KM
    Avian Dis; 2013 Dec; 57(4):750-5. PubMed ID: 24597117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collaborative study for the validation of serological methods for potency testing of diphtheria toxoid vaccines-part 1.
    Winsnes R; Sesardic D; Daas A; Behr-Gross ME
    Pharmeuropa Bio; 2004 Jan; 2003(2):35-68. PubMed ID: 14960262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection from clinical disease against three highly virulent strains of Newcastle disease virus after in ovo application of an antibody-antigen complex vaccine in maternal antibody-positive chickens.
    Kapczynski DR; Martin A; Haddad EE; King DJ
    Avian Dis; 2012 Sep; 56(3):555-60. PubMed ID: 23050473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination against Newcastle disease with a recombinant baculovirus hemagglutinin-neuraminidase subunit vaccine.
    Nagy E; Krell PJ; Dulac GC; Derbyshire JB
    Avian Dis; 1991; 35(3):585-90. PubMed ID: 1953580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of
    Aly SE; Hussein HA; Aly AM; Abdel-Baky MH; El-Sanousi AA
    Vet World; 2018 Sep; 11(9):1222-1228. PubMed ID: 30410225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.